Drug Search Results
More Filters [+]

LEO-90100

Alternative Names: leo-90100, leo90100, leo 90100
Latest Update: 2024-05-07
Latest Update Note: News Article

Product Description

Enstilar Foam (LEO 90100) on the hypothalamic-pituitary-adrenal (HPA) axis and calcium metabolism in subjects with extensive psoriasis vulgaris

Mechanisms of Action: GR Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Topical

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: LEO Pharma
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for LEO-90100

Countries in Clinic: China

Active Clinical Trial Count: 2

Highest Development Phases

Phase 3: Psoriasis

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

LP0053-2277

P3

Completed

Psoriasis

2024-02-23

57%

CTR20223222

P3

Recruiting

Psoriasis

None

Recent News Events